402 related articles for article (PubMed ID: 26539983)
1. Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.
Sloan DD; Lam CY; Irrinki A; Liu L; Tsai A; Pace CS; Kaur J; Murry JP; Balakrishnan M; Moore PA; Johnson S; Nordstrom JL; Cihlar T; Koenig S
PLoS Pathog; 2015; 11(11):e1005233. PubMed ID: 26539983
[TBL] [Abstract][Full Text] [Related]
2. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
Sung JA; Pickeral J; Liu L; Stanfield-Oakley SA; Lam CY; Garrido C; Pollara J; LaBranche C; Bonsignori M; Moody MA; Yang Y; Parks R; Archin N; Allard B; Kirchherr J; Kuruc JD; Gay CL; Cohen MS; Ochsenbauer C; Soderberg K; Liao HX; Montefiori D; Moore P; Johnson S; Koenig S; Haynes BF; Nordstrom JL; Margolis DM; Ferrari G
J Clin Invest; 2015 Nov; 125(11):4077-90. PubMed ID: 26413868
[TBL] [Abstract][Full Text] [Related]
3. SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.
Dashti A; Waller C; Mavigner M; Schoof N; Bar KJ; Shaw GM; Vanderford TH; Liang S; Lifson JD; Dunham RM; Ferrari G; Tuyishime M; Lam CK; Nordstrom JL; Margolis DM; Silvestri G; Chahroudi A
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817214
[TBL] [Abstract][Full Text] [Related]
4. Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART
Tuyishime M; Dashti A; Faircloth K; Jha S; Nordstrom JL; Haynes BF; Silvestri G; Chahroudi A; Margolis DM; Ferrari G
Front Immunol; 2021; 12():710273. PubMed ID: 34484212
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
6. Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules.
Pollara J; Edwards RW; Jha S; Lam CK; Liu L; Diedrich G; Nordstrom JL; Huffman T; Pickeral JA; Denny TN; Permar SR; Ferrari G
Front Immunol; 2020; 11():713. PubMed ID: 32373131
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
[TBL] [Abstract][Full Text] [Related]
8. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
9. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
10. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.
Tuyishime M; Garrido C; Jha S; Moeser M; Mielke D; LaBranche C; Montefiori D; Haynes BF; Joseph S; Margolis DM; Ferrari G
J Clin Invest; 2020 Oct; 130(10):5157-5170. PubMed ID: 32584790
[TBL] [Abstract][Full Text] [Related]
11. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a Novel Humanized Mouse Model To Investigate
Flerin NC; Bardhi A; Zheng JH; Korom M; Folkvord J; Kovacs C; Benko E; Truong R; Mota T; Connick E; Jones RB; Lynch RM; Goldstein H
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626677
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534
[TBL] [Abstract][Full Text] [Related]
14. Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses.
Prévost J; Richard J; Medjahed H; Alexander A; Jones J; Kappes JC; Ochsenbauer C; Finzi A
J Virol; 2018 Jul; 92(13):. PubMed ID: 29669829
[TBL] [Abstract][Full Text] [Related]
15. Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts.
Madhavi V; Kulkarni A; Shete A; Lee WS; Mclean MR; Kristensen AB; Ghate M; Wines BD; Hogarth PM; Parsons MS; Kelleher A; Cooper DA; Amin J; Emery S; Thakar M; Kent SJ;
J Acquir Immune Defic Syndr; 2017 Jul; 75(3):345-353. PubMed ID: 28346319
[TBL] [Abstract][Full Text] [Related]
16. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients.
Bouchat S; Gatot JS; Kabeya K; Cardona C; Colin L; Herbein G; De Wit S; Clumeck N; Lambotte O; Rouzioux C; Rohr O; Van Lint C
AIDS; 2012 Jul; 26(12):1473-82. PubMed ID: 22555163
[TBL] [Abstract][Full Text] [Related]
17. A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4
Grau-Expósito J; Serra-Peinado C; Miguel L; Navarro J; Curran A; Burgos J; Ocaña I; Ribera E; Torrella A; Planas B; Badía R; Castellví J; Falcó V; Crespo M; Buzon MJ
mBio; 2017 Jul; 8(4):. PubMed ID: 28698276
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction.
Yang H; Wallace Z; Dorrell L
Front Immunol; 2018; 9():2861. PubMed ID: 30564246
[TBL] [Abstract][Full Text] [Related]
19. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
[TBL] [Abstract][Full Text] [Related]
20. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.
Liu L; Patel B; Ghanem MH; Bundoc V; Zheng Z; Morgan RA; Rosenberg SA; Dey B; Berger EA
J Virol; 2015 Jul; 89(13):6685-94. PubMed ID: 25878112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
